Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
In recent years, elevated triglyceride (TG) levels have attracted increasing attention as a residual cardiovascular risk factor in patients with chronic kidney disease (CKD). Pemafibrate, a selective peroxisome proliferator-activated receptor αmodulator and a novel therapeutic option for hypertriglyceridemia in patients with CKD, has been reported to cause fewer kidney-related adverse events than conventional fibrates. Although appropriate management of hypertriglyceridemia may contribute to improved renal outcomes, evidence for the renoprotective effects of pemafibrate has not yet been established. The aim of this study is to investigate the effect of pemafibrate on the eGFR slope in patients with CKD.
The JKAPI-CKD study is a multicenter, open-label, randomized controlled trial. Eligible participants are adults (≥18 years) with CKD and hypertriglyceridemia who have not received pemafibrate or any fibrate therapy within 12 weeks prior to enrollment. Key inclusion criteria are: (i) eGFR 20≤, <60 mL/min/1.73 m², and (ii) fasting TG ≥150 mg/dL or non-fasting TG ≥175 mg/dL. Participants will be randomized in a 1:1 ratio to either the pemafibrate treatment group (standard therapy plus pemafibrate 0.1–0.4 mg/day) or the control treatment group (standard therapy according to guidelines, excluding fibrates). The target sample size is 2,200 participants, and the observation period is 112 weeks. The primary endpoint is the chronic eGFR slope, defined as the eGFR slope from week 12 to week 104.
Participant enrollment and follow-up are ongoing.
The JKAPI-CKD study will provide new insights into the potential renoprotective effects of pemafibrate in CKD patients with hypertriglyceridemia. The findings are expected to establish novel evidence for the treatment of hypertriglyceridemia with pemafibrate in patients with CKD. （Clinical trial registration: jRCTs031240097）
